



LUND UNIVERSITY

Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck squamous cell carcinoma xenografts exposed to surgical trauma.

Lindgren, Gustaf; Ekblad, Lars; Vallon-Christersson, Johan; Kjellén, Elisabeth; Gebre-Medhin, Maria; Wennerberg, Johan

Published in:
BMC Cancer

DOI:
[10.1186/1471-2407-14-648](https://doi.org/10.1186/1471-2407-14-648)

2014

[Link to publication](#)

Citation for published version (APA):

Lindgren, G., Ekblad, L., Vallon-Christersson, J., Kjellén, E., Gebre-Medhin, M., & Wennerberg, J. (2014). Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck squamous cell carcinoma xenografts exposed to surgical trauma. *BMC Cancer*, 14, Article 648. <https://doi.org/10.1186/1471-2407-14-648>

Total number of authors:
6

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

RESEARCH ARTICLE

Open Access

Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck squamous cell carcinoma xenografts exposed to surgical trauma

Gustaf Lindgren^{1*}, Lars Ekblad², Johan Vallon-Christersson², Elisabeth Kjellén², Maria Gebre-Medhin² and Johan Wennerberg¹

Abstract

Background: Several studies on the use of erythropoietin (Epo) to treat anaemia in patients undergoing cancer treatment have shown adverse effects on tumour control and survival. Experimental studies indicate that this could be linked to an interaction with wound healing processes and not an effect on tumour cells *per se*. We have previously shown that erythropoietin in combination with surgical trauma stimulates tumour growth. In the present study, we investigated the effect of surgery and Epo on gene expression.

Methods: Human tumours from oral squamous cell cancer were xenotransplanted to nude mice treated with Epo. The tumours were then transected in a standardised procedure to mimic surgical trauma and the change in gene expression of the tumours was investigated by microarray analysis. qRT-PCR was used to measure the levels of mRNAs of pro-apoptotic genes. The frequency of apoptosis in the tumours was assessed using immunohistochemistry for caspase-3.

Results: There was little change in the expression of genes involved in tumour growth and angiogenesis but a significant down-regulation of the expression of genes involved in apoptosis. This effect on apoptosis was confirmed by a general decrease in the expression of mRNA for selected pro-apoptotic genes. Epo-treated tumours had a significantly lower frequency of apoptosis as measured by immunohistochemistry for caspase 3.

Conclusions: Our results suggest that the increased tumour growth during erythropoietin treatment might be due to inhibition of apoptosis, an effect that becomes significant during tissue damage such as surgery. This further suggests that the decreased survival during erythropoietin treatment might be due to inhibition of apoptosis.

Keywords: Erythropoietin, Head and neck cancer, Surgery, Apoptosis, Wound healing, Xenograft

Background

Squamous cell carcinoma of the head and neck (HNSCC) is globally a common disease. Annually, more than 147,500 cases and 63,300 attributed deaths are reported in Europe [1,2] and the prognosis for clinically advanced cancer is still very poor. It often affects patients with severe co-morbidity and both the cancer

and the treatment, such as surgery, radiotherapy, chemotherapy and combinations thereof, have strong adverse effects on the patient's general condition and nutritional status. Weight loss and anaemia are common. It has been argued that increased blood flow and oxygenation in the tumours would make them more accessible to radiotherapy and chemotherapy [3-5]. Erythropoietin (Epo) has been advocated to increase haemoglobin concentrations with the intent of improving the effect of radiotherapy and the quality of life.

* Correspondence: gustaf.lindgren@med.lu.se

¹Department of Otorhinolaryngology/Head and Neck Surgery, Lund University Hospital, SE-22185 Lund, Sweden

Full list of author information is available at the end of the article

Early studies of Epo treatment in cancer patients primarily investigated the effects on haemoglobin level [3-6] and quality of life [7]. Few studies had tumour growth, disease free survival and overall survival as primary end-points. In 2003, a study [8] revealed significantly worse outcome for HNSCC patients treated with Epo. Other studies involving Epo administration during treatment of non-small-cell carcinoma of the lung (NSCLC) [7] and breast cancer [9] also showed lower survival rates for Epo treated patients. These results raised the concern that Epo might stimulate tumour growth. Epo has also been implicated in tumour invasiveness [10-12]. Several studies on the use of Epo to ameliorate anaemia in patients undergoing cancer treatment have shown adverse effects on tumour control and survival.

We have previously shown that Epo in combination with surgical trauma can stimulate growth of xenotransplanted tumours [13], while there was no growth stimulating effect of Epo alone. Later, we showed that the combination effect of Epo and surgery did not involve a direct interaction between Epo and the tumour cells [14].

In the present work, we analysed xenografted tumours using DNA microarrays in order to establish which cellular pathways that might be affected by Epo when combined with surgery.

Methods

Tumour line

The tumour line LU-HNSCC-7 was originally established from a moderately differentiated squamous cell carcinoma of the bucca (T2N0M0). It is aneuploid and without p53 mutation or cyclin D1 gene amplification [15].

Establishment of xenograft

The study was approved by the Swedish National Board for Care of Laboratory Animals (M-48-06). The xenografts were established using a previously described method [16]. Tumour sample from the tumour line LU-HNSCC-7 were inoculated subcutaneously in the flank of BALB/c nude mice. Tumour volume was calculated from orthogonal diameter measurements every two or three days using the formula:

$$V = \frac{L \times W^2}{2}$$

Where V = volume, L = length, and W = width


The mice were also weighed regularly. Tumours with a volume of smaller than 40 mm³ or greater than 300 mm³ at the time of surgery were excluded from the analysis, so were animals showing weight loss in order to ensure undisturbed logarithmic growth.

Administration of erythropoietin

Recombinant human Epo (NeoRecormone, Roche; 400 IU/kg body weight) or physiological saline (placebo) was administered by subcutaneous injection (10 µL/g body weight) every third day starting from the day of transplantation.

Surgical procedure and sampling of tumours

Tumour bearing mice were treated with subcutaneous injections of Epo (NeoRecormone, Roche; 400 IU/kg body weight) or physiological saline (placebo) (10 µL/g body weight) every third day starting from the day of transplantation (Figure 1). After 12 days, the tumours were subjected to a standardised surgical trauma with a



subcutaneous transection of the tumour using an injection needle. The tumours were collected for analysis at the indicated time points after surgery. Separate sets of tumours were established in an identical manner for the analysis of mRNA by microarray and qRT-PCR, and for the analysis of apoptosis.

Histological verification

The establishment of the solid malignant xenografts was confirmed using histological examination with hematoxylin

and eosin staining performed in conjunction with the harvesting of tumours.

Microarrays

RNA was extracted from the tumour samples and microarray hybridisation was performed using the Illumina Human-6 Expression BeadChip KitVersion-2 (Illumina Inc., San Diego, CA, USA). The scanning was performed on Illumina Bead Array Reader (Illumina Inc., San Diego, CA, USA). The analysis of the fluorescent signals was




Figure 2 qRT-PCR analysis of pro-apoptotic genes. The bars show the increase in gene expression in Epo- compared to placebo-treated tumours measured after **A.** 1 h ($P < 0.0001$), **B.** 12 h ($P = 0.0005$), **C.** 24 h ($P = 0.0003$), **D.** 48 h ($P = 0.66$), and **E.** 72 h ($P = 0.20$). The influence of Epo was analysed by 2-way ANOVA. Error bars represent SEM.

performed using Multiexperiment Viewer software (MeV, Dana-Farber Cancer Institute, Boston, MA).

Quantification of mRNA by qRT-PCR

Extraction of RNA was done with the AllPrep DNA/RNA Mini kit from Qiagen (Hilden, Germany) according to the manufacturer's instructions. The expression of mRNA was measured by TaqMan gene expression assays from Applied Biosystems (Carlsbad, CA, USA) (DIP, BCL2L13, CASP1, MIF, CARD10, AIFM1, BIK, and BID with FAM labelled probes, ID: Hs00209789_m1, Hs00354836_m1, Hs00354836_m1, Hs00236988_g1, Hs00367225_m1, Hs00377585_m1, Hs00609635_m1, and Hs00609632_m1 respectively, and GAPDH with a VIC labelled probe, cat. no: 4326317E) with the Rotor-Gene Multiplex RT-PCR kit (QIAGEN, Hilden, Germany) in a Rotor-Gene RG-3000 (Corbette Research, St. Neots, UK) with the following program: reverse transcription 15 min, 50°C followed by 5 min at 95°C and then 15 s at 95°C and 15 s at 60°C in 40 cycles.

Immunohistochemical analysis of apoptosis

Tumours were cut in 4-µm sections and stained using the TechMate 500 autostainer (Ventana Biotek, Tucson, AZ, USA). The primary antibody was anti-active caspase-3 antibody (cat. no. AF835, R&D Systems, Minneapolis, MN, USA). ChemMate EnVision Detection Kit (DakoCytomation, Glostrup, Denmark) was used for detection. In each of the tumour samples, the number of stained apoptotic cells was counted in three fields with a 40× objective.

Statistical methods

For the microarray analysis normalized data was filtered on a p-detection value <0.05. The intensities were log2 transformed and the rows were centred on the mean. A SAM 2-way ANOVA analysis for Epo-significant genes was performed for the surgery groups using the results of the untreated tumours as reference (group, Figure 2). All tumours were compared using the DAVID (Database for Annotation, Visualization and Integrated Discovery) [17,18] functional clustering tool. The likelihood of an

enrichment of the genes involved in different biological pathways and themes was determined using EASE-score [19] which is a modified and more stringent form of Fisher Exact P-Value.

The qRT-PCR results were analysed by 2-way ANOVA and in the apoptosis analysis the groups were compared using an independent samples Mann–Whitney test.

Results

Microarray analysis

For the DNA microarray analysis, five tumours were set up in a total of six groups – three receiving Epo and three placebo (Figure 1). Of the tumours, three were excluded as the tumour sizes were outside the set limits and one due to failed hybridization. The tumours were analysed at two time points, 24 and 48 hours after surgery, since our previous results showed that the main effect of Epo ended within 48 hours after surgery and we were interested in early processes within this interval [13]. A total of 13,461 genes were analyzed. The microarray data was deposited at the Gene Expression Omnibus (GEO) at the National Center for Biotechnology Information (NCBI) (see Additional file 1).

In line with previous results, showing that the cell line LU-HNSCC-7 does not express the Epo receptor (EpoR) [14], this receptor was not significantly expressed in the microarray samples. This was also true for Epo.

A combined 2-way ANOVA analysis of all groups having undergone surgery (group 3–6) showed 1371 Epo-significant genes.

The functional clustering tool DAVID was used to analyse the enrichment of differentially expressed genes in cellular pathways when comparing Epo versus non-Epo treated tumours at the different time points after surgery. Many pathways were significantly enriched at one or several of the time points. However, we focussed the analysis on pathways that might be of importance for tumour growth. None of these pathways were enriched when comparing the control tumours that had not been subjected to surgery (data not shown). For the surgery groups tumour growth, cell cycle control and angiogenesis

Table 1 Analysis of the gene expression data using the DAVID functional annotation tool

Biological theme (pathway)	24 h		48 h		24 and 48 h	
	Genes (No)	P-value	Genes (No)	P-value	Genes (No)	P-value
Apoptosis	81	6.0×10^{-4}	97	3.0×10^{-2}	20	1.5×10^{-4}
Programmed cell death	82	6.0×10^{-4}	99	6.0×10^{-4}	19	3.7×10^{-4}
VEGF-signalling	8	5.5×10^{-1}	12	2.5×10^{-1}	0	n.a.
Angiogenesis	9	9.7×10^{-1}	0	n.a.	0	n.a.
Blood vessel development	20	8.3×10^{-1}	0	n.a.	0	n.a.
Response to hypoxia	0	n.a.	0	n.a.	0	n.a.

NOTE The table shows the number of genes with significantly altered expression involved in pathways related to angiogenesis, hypoxia and apoptosis. The p-value was defined as the EASE score which is a more stringent form of Fishers exact p-value.




Figure 3 Analysis of apoptosis using immunohistochemistry for caspase-3. The combined number of apoptoses counted per tumour sample in Epo- and placebo-treated groups 24 and 48 hours after surgery respectively.

were not enriched (Table 1). However, there was a significant enrichment of genes involved in apoptotic pathways, both 24 and 48 hours after surgery (Table 1). A further analysis of the differentially expressed genes included in these pathways showed that pro-apoptotic genes tended to be down-regulated.

Quantification of mRNA by qRT-PCR

To verify the down-regulation of pro-apoptotic genes seen in the microarray analysis we selected 7 genes involved in apoptosis (DIP, BCL2L13, CASP1, CARD10, AIFM1, BIK

and BID), all displaying decreased expression in the DNA microarray analysis, and performed qRT-PCR to measure the gene expression. This analysis was performed on a separate set of tumours that had not been included in the microarray analysis. Twelve groups of tumours were analysed: two groups each (+/-Epo) 1, 12, 24, 48, and 72 hours after surgical transection.

We chose to collect tumours 12 hours after surgery presuming that the effect on transcription would precede the response at protein and cellular levels. There was no effect after 72 hours (data not shown).

We analysed the mRNA level for the following genes, which all displayed decreased expression in the DNA microarray analysis: DIP, BCL2L13, CASP1, CARD10, AIFM1, BIK and BID. The expression of the set of pro-apoptotic genes was significantly decreased at the 1 and 12 hour time points ($P < 0.0001$ and $P = 0.0005$ respectively). At 24 hours there was an increase in expression ($P = 0.0003$), while there was no significant difference at 48 and 72 hours (Figure 2). This indicates an early decrease in the expression of pro-apoptotic genes, followed by a transient up-regulation 24 hours after surgery and then returning to basal expression after 48 hours.

Immunohistochemical assessment of apoptosis

As a further confirmation of the effect on apoptosis, a separate set of tumours was analysed by immunohistochemistry. The expression of active caspase-3 was measured 24 and 48 h after surgery with or without Epo-treatment. There was a significant decrease in Caspase-3 expression in the Epo- compared with the placebo-treated tumours




Figure 4 Immunohistochemical staining for caspase 3 on surgically transected tumours. A) Epo-treated tumour 24 hours after surgery. B) Placebo-treated tumour 24 hours after surgery. C) Placebo-treated tumour 48 hours after surgery

at both time points ($P = 0.045$ at 24 h and $P = 0.030$ at 48 h) (Figures 3 and 4).

Discussion

Originally, the stimulating effect of erythropoietin on HNSCC has been assumed to involve angiogenesis and tumour hypoxia. Therefore, an initial assumption in this work was that pathways involved in these activities would be affected. However, we found little change in the expression of genes involved in growth and angiogenesis but, on the other hand, we found an interesting decrease in the expression of pro-apoptotic genes. These results were further verified by qRT-PCR and immunohistochemical analysis of apoptosis.

In normal erythropoiesis, Epo has important apoptosis-inhibiting effects [20,21] and it has also been shown to protect hypoxic neurons from apoptosis [22]. Earlier data suggest that this effect does not become apparent when Epo is given alone but when the tumour is subject to some kind of concurrent stress, for example cisplatin treatment [5] or irradiation [23].

Surgical trauma can also stimulate proliferation through wound healing [24]. Many mechanisms in wound healing, e.g. paracrine growth factor signalling [25], angiogenesis [26] and DNA-replication initiation [27] are also disturbed in tumorigenesis, showing a close connection between the mechanisms of wound healing and tumour development and growth. We have previously seen increased tumour growth *in vivo* for this cell line after surgery while under Epo-treatment [13] but not at a cellular level *in vitro* [14], and the cell line was shown not to express the Epo receptor [14]. This suggests that Epo exerts its effect through interaction with stroma cells.

A hypothesis derived from the present study is that the early wound healing response (resulting from the surgical procedure) in combination with a secondary effect of Epo, mediated by stromal cells, suppresses the apoptotic potential within the tumour. The apoptosis-inhibiting effect of erythropoietin can be the common mechanism for the increased tumour survival when it is combined with any treatment – surgery, radiation or chemotherapy.

Wound healing is a long multi-stage process involving inflammatory, proliferative and proliferative phases. In this study, we focused on the early inflammatory phase since it was during the first 48 hours that we previously had seen a growth delay in this model [13].

Our findings have important clinical consequences since this model of surgical trauma can be applicable to minimal residual disease after surgery. The remaining tumour tissue remains susceptible to the wound healing response in which Epo signalling plays a role [26]. It is particularly interesting considering the result of the study by Henke *et al.* since they found a particularly

worse prognosis in their stratum 2, i.e. those patients who underwent incomplete surgery and received erythropoietin during postoperative radiotherapy [8]. It must be pointed out that a diagnostic biopsy also induces a surgical trauma and a subsequent wound healing process. The result also underlines the possibility of an anti-apoptotic approach in future cancer treatment.

Conclusions

For the understanding of tumour survival and growth, we must not only consider the innate properties of the tumour cells. We must also take into account the almost parasitic approach with which the tumour interacts with the surrounding stroma.

Surgery damages tissue and triggers a stressful wound healing response. The use of antiapoptotic substances, such as Epo, increases tumour cell survival when the tissue is under stress. The use of Epo to patients undergoing tumour treatment, including surgery, is therefore counterproductive and possibly hazardous.

Additional file

Additional file 1: Microarray data are deposited and available at the Gene Expression Omnibus (GEO) at the National Center for Biotechnology Information (NCBI). <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58194>.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

GL, LE, EK and JW participated in the design of the study and the drafting of the manuscript. J VC participated in the microarray analysis. LE and M GM performed the qRT-PCR analysis. All authors read and approved of the final manuscript.

Acknowledgements

Our work was supported by the Swedish Cancer Society, the King Gustaf V Jubilee Fund, Governmental funding of clinical research within the National Health System Region of Scandia R&D funding, the Foundations of the Lund University Hospital, the Gunnar Nilsson Cancer Foundation, the Crafoord Foundation, the Berta Kamprad Foundation for Investigation and Control of Cancer Diseases and the Laryngology Fund.

Author details

¹Department of Otorhinolaryngology/Head and Neck Surgery, Lund University Hospital, SE-22185 Lund, Sweden. ²Department of Oncology, Lund University Hospital, Lund, Sweden.

Received: 19 June 2013 Accepted: 31 July 2014

Published: 2 September 2014

References

1. Ferlay J, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN. *Int J Cancer* 2008, **112**:765–781.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. *Ann Oncol* 2007, **18**:582–592.
3. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. *Cancer* 1999, **86**(8):1528–1536.

4. Frommhold H, Guttenberger R, Henke M: **The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience.** *Strahlenther Onkol* 1998, **174**(Suppl 4):31–34.
5. Silver DF, Piver MS: **Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect.** *Gynecol Oncol* 1999, **73**(2):280–284.
6. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS: **Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx.** *Int J Radiat Oncol Biol Phys* 2001, **50**(3):705–715.
7. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN: **Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.** *J Clin Oncol* 2007, **25**(9):1027–1032.
8. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: **Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.** *Lancet* 2003, **362**(9392):1255–1260.
9. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen: **Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.** *J Clin Oncol* 2005, **23**(25):5960–5972.
10. Lai SY, Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR: **Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.** *Oncogene* 2005, **24**(27):4442–4449.
11. Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G, Verma A: **Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.** *Neoplasia* 2005, **7**(5):537–543.
12. Abhold E, Rahimy E, Wang-Rodriguez J, Blair KJ, Yu MA, Brumund KT, Weisman RA, Ongkeko WM: **Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro.** *BMC Res Notes* 4:553.
13. Kjellen E, Sasaki Y, Kjellstrom J, Zackrisson B, Wennerberg J: **Recombinant erythropoietin beta enhances growth of xenografted human squamous cell carcinoma of the head and neck after surgical trauma.** *Acta Otolaryngol* 2006, **126**(5):545–547.
14. Sasaki Y, Kjellen E, Mineta H, Wennerberg J, Ekblad L: **No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo.** *Acta Oncol* 2009, **48**(7):1062–1069.
15. Henriksson E, Baldetorp B, Borg A, Kjellen E, Akervall J, Wennerberg J, Wahlberg P: **p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck.** *Acta Oncol* 2006, **45**(3):300–305.
16. Wennerberg J: **Changes in growth pattern of human squamous-cell carcinomas of the head and neck during serial passages in nude mice.** *Int J Cancer* 1984, **33**(2):245–250.
17. da Huang W, Sherman BT, Lempicki RA: **Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.** *Nat Protoc* 2009, **4**(1):44–57.
18. da Huang W, Sherman BT, Lempicki RA: **Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.** *Nucleic Acids Res* 2009, **37**(1):1–13.
19. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA: **Identifying biological themes within lists of genes with EASE.** *Genome Biol* 2003, **4**(10):R70.
20. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nuñez G, Fernandez-Luna JL: **Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines.** *J Biol Chem* 1999, **274**(32):22165–22169.
21. Dolznig H, Habermann B, Stangl K, Deiner EM, Moriggl R, Beug H, Mullner EW: **Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts.** *Curr Biol* 2002, **12**(13):1076–1085.
22. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M: **Erythropoietin Receptor-mediated Inhibition of Exocytotic Glutamate Release Confers Neuroprotection during Chemical Ischemia.** *J Biol Chem* 2001, **276**:39469–39475.
23. Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, Blackwell KL: **Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity.** *Mol Cancer Ther* 2006, **5**(2):356–361.
24. Ekblad L, Lindgren G, Persson E, Kjellen E, Wennerberg J: **Cell-line-specific stimulation of tumor cell aggressiveness by wound healing factors – a central role for STAT3.** *BMC Cancer* 2013, **13**(1):33.
25. Elenbaas B, Weinberg RA: **Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation.** *Exp Cell Res* 2001, **264**(1):169–184.
26. Haroon ZA, Amin K, Jiang X, Arcasoy MO: **A novel role for erythropoietin during fibrin-induced wound-healing response.** *Am J Pathol* 2003, **163**(3):993–1000.
27. Riss J, Khanna C, Koo S, Chandramouli GV, Yang HH, Hu Y, Kleiner DE, Rosenwald A, Schaefer CF, Ben-Sasson SA, Yang L, Powell J, Kane DW, Star RA, Aprelikova O, Bauer K, Vasselli JR, Maranchie JK, Kohn KW, Buetow KH, Linehan WM, Weinstein JN, Lee MP, Klausner RD, Barrett JC: **Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma.** *Cancer Res* 2006, **66**(14):7216–7224.

doi:10.1186/1471-2407-14-648

Cite this article as: Lindgren et al.: Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck squamous cell carcinoma xenografts exposed to surgical trauma. *BMC Cancer* 2014 **14**:648.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

